 The goal of this clinical research study is to learn if giving PEG-Alpha Interferon PEG-Intron and Sargramostim GM-CSF to patients receiving treatment with high dose Gleevec imatinib mesylate is more effective in treating CML in chronic phase than therapy with imatinib mesylate alone. 